PMADS

Id:	acc0371
Group:	1sens
Protein:	S6
Gene Symbol:	RPS6
Protein Id:	P62753
Protein Name:	RS6_HUMAN
PTM:	phosphorylation
Site:	Ser244
Site Sequence:	SSLRASTSKSESSQK------
Disease Category:	Cancer
Disease:	Glioblastoma
Disease Subtype:
Disease Cellline:	U87-MG
Disease Info:
Drug:	XL765 (SAR245409)
Drug Info:	XL765 (SAR245409) is an oral dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) that was investigated in clinical trials for the treatment of advanced malignancies.
Effect:	modulate
Effect Info:	"XL765 can effectively inhibit the phosphorylation of AKT, p70S6K, and S6 in multiple tumor cell lines, thereby inhibiting tumor growth."
Note:
Score:	4.0
Pubmed(PMID):	24634413
Sentence Index:	24634413_4
Sentence:	"In cellular assays, XL765 inhibits the formation of PIP(3) in the membrane, and inhibits phosphorylation of AKT, p70S6K, and S6 phosphorylation in multiple tumor cell lines with different genetic alterations affecting the PI3K pathway."

Sequence & Structure:

MKLNISFPATGCQKLIEVDDERKLRTFYEKRMATEVAADALGEEWKGYVVRISGGNDKQGFPMKQGVLTHGRVRLLLSKGHSCYRPRRTGERKRKSVRGCIVDANLSVLNLVIVKKGEKDIPGLTDTTVPRRLGPKRASRIRKLFNLSKEDDVRQYVVRKPLNKEGKKPRTKAPKIQRLVTPRVLQHKRRRIALKKQRTKKNKEEAAEYAKLLAKRMKEAKEKRQEQIAKRRRLSSLRASTSKSESSQK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
RPS6	ATALUREN	80S Ribosome modulator	4	-	Duchenne muscular dystrophy	EMA
RPS6	ATALUREN	80S Ribosome modulator	3	Completed	Duchenne muscular dystrophy	ClinicalTrials ClinicalTrials ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	3	Completed	cystic fibrosis	ClinicalTrials ClinicalTrials ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	3	Terminated	cystic fibrosis	ClinicalTrials ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	3	Completed	Becker muscular dystrophy	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	3	Completed	qualitative or quantitative defects of dystrophin	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	3	Enrolling by invitation	Duchenne muscular dystrophy	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	3	Terminated	Duchenne muscular dystrophy	ClinicalTrials
RPS6	MT-3724	80S Ribosome inhibitor	2	Terminated	diffuse large B-cell lymphoma	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Completed	epilepsy	ClinicalTrials
RPS6	MT-3724	80S Ribosome inhibitor	2	Terminated	non-Hodgkins lymphoma	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Terminated	hemophilia A	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Completed	Duchenne muscular dystrophy	ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Terminated	Duchenne muscular dystrophy	ClinicalTrials ClinicalTrials ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Completed	cystic fibrosis	ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials
RPS6	ELX-02	80S Ribosome modulator	2	Completed	cystic fibrosis	ClinicalTrials ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Terminated	Becker muscular dystrophy	ClinicalTrials ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Completed	Becker muscular dystrophy	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Terminated	hemophilia B	ClinicalTrials
RPS6	ELX-02	80S Ribosome modulator	2	Recruiting	Alport syndrome	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Completed	aniridia	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Withdrawn	aniridia	ClinicalTrials
RPS6	ELX-02	80S Ribosome modulator	2	Terminated	cystinosis	ClinicalTrials
RPS6	ATALUREN	80S Ribosome modulator	2	Terminated	Disorder of amino acid and other organic acid metabolism	ClinicalTrials
RPS6	MT-3724	80S Ribosome inhibitor	1	Terminated	neoplasm of mature B-cells	ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

RPS6-Ser148
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6-Ser235
Cancer	Intensity
BRCA	1.184
COAD
HGSC
ccRCC	-0.383
GBM	0.073
HNSC	0.382
LUAD	0.449
LUSC	0.94
non_ccRCC	-2.268
PDAC	-0.16
UCEC	-0.215

RPS6-Ser236
Cancer	Intensity
BRCA	1.399
COAD	0.214
HGSC
ccRCC	-0.441
GBM	0.023
HNSC	0.338
LUAD	0.407
LUSC	0.907
non_ccRCC	-2.362
PDAC	-0.214
UCEC	-0.27

RPS6-Ser240
Cancer	Intensity
BRCA	1.329
COAD	-0.99
HGSC	0.145
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC	-0.484
UCEC

RPS6-Ser242
Cancer	Intensity
BRCA
COAD	-0.542
HGSC	1.154
ccRCC
GBM
HNSC	-0.612
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6-Ser82
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.321
HNSC	-0.485
LUAD	-0.564
LUSC	2.03
non_ccRCC
PDAC	-0.381
UCEC	-0.278

RPS6-Tyr84
Cancer	Intensity
BRCA	-0.503
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-0.443
LUSC	1.498
non_ccRCC
PDAC	-0.552
UCEC

RPS6KA1-Ser218
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC	0.707
UCEC	-0.707

RPS6KA1-Ser230
Cancer	Intensity
BRCA
COAD	0.199
HGSC	1.332
ccRCC
GBM
HNSC	-0.855
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.676

RPS6KA1-Ser28
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.311
GBM
HNSC
LUAD	-0.05
LUSC	-1.328
non_ccRCC
PDAC	1.067
UCEC

RPS6KA1-Ser372
Cancer	Intensity
BRCA	0.233
COAD	-0.684
HGSC	2.371
ccRCC	-0.505
GBM	0.694
HNSC	-0.745
LUAD	-0.088
LUSC	0.644
non_ccRCC	-1.42
PDAC	-0.202
UCEC	-0.296

RPS6KA1-Ser378
Cancer	Intensity
BRCA	-0.001
COAD	-1.356
HGSC
ccRCC	-1.574
GBM	1.362
HNSC	1.141
LUAD	0.66
LUSC	0.113
non_ccRCC	-0.073
PDAC
UCEC	-0.27

RPS6KA1-Ser389
Cancer	Intensity
BRCA	-0.926
COAD	-0.393
HGSC	2.613
ccRCC	-0.217
GBM	-0.311
HNSC	-0.007
LUAD	-0.099
LUSC	0.478
non_ccRCC	-1.325
PDAC	0.04
UCEC	0.147

RPS6KA1-Ser522
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-0.791
LUSC
non_ccRCC	1.124
PDAC
UCEC	-0.333

RPS6KA1-Ser54
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.476
GBM
HNSC	-1.836
LUAD	0.264
LUSC	0.576
non_ccRCC	-0.041
PDAC	-0.68
UCEC	1.24

RPS6KA1-Ser693
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA1-Ser696
Cancer	Intensity
BRCA	0.042
COAD	-1.377
HGSC
ccRCC	-0.299
GBM	2.161
HNSC	-0.573
LUAD	-0.925
LUSC	-0.023
non_ccRCC	1.027
PDAC	0.212
UCEC	-0.244

RPS6KA1-Ser81
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.665
GBM
HNSC
LUAD	0.358
LUSC	0.464
non_ccRCC	-1.488
PDAC
UCEC

RPS6KA1-Thr234
Cancer	Intensity
BRCA	-0.481
COAD	-0.141
HGSC	2.489
ccRCC	-0.603
GBM	-0.123
HNSC	0.098
LUAD	-0.085
LUSC	0.818
non_ccRCC	-1.463
PDAC	-0.584
UCEC	0.076

RPS6KA1-Thr368
Cancer	Intensity
BRCA	-1.456
COAD	0.005
HGSC
ccRCC	-0.039
GBM	0.705
HNSC	-1.287
LUAD	-0.001
LUSC	1.758
non_ccRCC	-0.385
PDAC
UCEC	0.7

RPS6KA1-Thr393
Cancer	Intensity
BRCA
COAD	-0.738
HGSC	0.361
ccRCC	-0.874
GBM
HNSC	1.25
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA1-Thr582
Cancer	Intensity
BRCA	-0.952
COAD	0.136
HGSC	0.538
ccRCC	-0.595
GBM	2.708
HNSC	-0.471
LUAD	-0.299
LUSC	0.054
non_ccRCC	-0.367
PDAC	-0.806
UCEC	0.054

RPS6KA1-Thr586
Cancer	Intensity
BRCA
COAD	-0.066
HGSC	1.854
ccRCC	-0.583
GBM
HNSC	0.095
LUAD	-0.224
LUSC
non_ccRCC	-1.076
PDAC
UCEC

RPS6KA1-Tyr237
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA1-Tyr585
Cancer	Intensity
BRCA
COAD	-0.524
HGSC	1.411
ccRCC	-0.489
GBM	0.03
HNSC	0.273
LUAD	0.909
LUSC
non_ccRCC
PDAC
UCEC	-1.61

RPS6KA2-Ser214
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC	0.707
UCEC	-0.707

RPS6KA2-Ser385
Cancer	Intensity
BRCA
COAD	-0.65
HGSC
ccRCC
GBM	-0.116
HNSC
LUAD	0.488
LUSC	-1.143
non_ccRCC	1.421
PDAC
UCEC

RPS6KA2-Ser389
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	0.707
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA2-Thr230
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	0.596
HNSC
LUAD	-0.205
LUSC	0.928
non_ccRCC
PDAC
UCEC	-1.319

RPS6KA2-Thr578
Cancer	Intensity
BRCA
COAD	-0.881
HGSC
ccRCC
GBM
HNSC
LUAD	1.087
LUSC
non_ccRCC	-0.205
PDAC
UCEC

RPS6KA2-Tyr685
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

RPS6KA3-Ser19
Cancer	Intensity
BRCA
COAD	-0.707
HGSC
ccRCC	0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA3-Ser215
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC	0.707
UCEC	-0.707

RPS6KA3-Ser227
Cancer	Intensity
BRCA
COAD	0.199
HGSC	1.332
ccRCC
GBM
HNSC	-0.855
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.676

RPS6KA3-Ser369
Cancer	Intensity
BRCA	-0.255
COAD	-0.304
HGSC	2.077
ccRCC	-0.493
GBM	0.043
HNSC	-0.148
LUAD	-0.202
LUSC	1.061
non_ccRCC	-2.014
PDAC	0.193
UCEC	0.044

RPS6KA3-Ser375
Cancer	Intensity
BRCA	-2.039
COAD	0.872
HGSC
ccRCC	0.187
GBM	-0.227
HNSC	0.737
LUAD	0.914
LUSC	0.448
non_ccRCC	-1.469
PDAC	0.502
UCEC	0.074

RPS6KA3-Ser386
Cancer	Intensity
BRCA	-0.989
COAD	-0.384
HGSC
ccRCC	-0.448
GBM	-0.368
HNSC	0.525
LUAD	0.047
LUSC	0.227
non_ccRCC	-0.822
PDAC	-0.324
UCEC	2.535

RPS6KA3-Ser396
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.707
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA3-Ser415
Cancer	Intensity
BRCA	-2.52
COAD	0.206
HGSC	1.033
ccRCC	0.431
GBM	0.057
HNSC	0.342
LUAD	0.285
LUSC	0.06
non_ccRCC	0.766
PDAC	0.491
UCEC	-1.15

RPS6KA3-Ser715
Cancer	Intensity
BRCA	-0.161
COAD	0.129
HGSC	1.234
ccRCC	0.088
GBM	-0.371
HNSC	1.479
LUAD	-2.181
LUSC	0.783
non_ccRCC	0.161
PDAC	-0.452
UCEC	-0.709

RPS6KA3-Ser78
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.665
GBM
HNSC
LUAD	0.358
LUSC	0.464
non_ccRCC	-1.488
PDAC
UCEC

RPS6KA3-Thr231
Cancer	Intensity
BRCA	-0.48
COAD	-0.14
HGSC	2.49
ccRCC	-0.603
GBM	-0.122
HNSC	0.09
LUAD	-0.084
LUSC	0.819
non_ccRCC	-1.463
PDAC	-0.583
UCEC	0.077

RPS6KA3-Thr365
Cancer	Intensity
BRCA	-0.677
COAD	-0.279
HGSC	2.645
ccRCC	-0.354
GBM	-0.114
HNSC	-0.074
LUAD	-0.24
LUSC	0.427
non_ccRCC	-1.44
PDAC	-0.006
UCEC	0.112

RPS6KA3-Thr577
Cancer	Intensity
BRCA	-0.952
COAD	0.136
HGSC	0.538
ccRCC	-0.595
GBM	2.708
HNSC	-0.471
LUAD	-0.299
LUSC	0.054
non_ccRCC	-0.367
PDAC	-0.806
UCEC	0.054

RPS6KA3-Thr581
Cancer	Intensity
BRCA
COAD	-0.066
HGSC	1.854
ccRCC	-0.583
GBM
HNSC	0.095
LUAD	-0.224
LUSC
non_ccRCC	-1.076
PDAC
UCEC

RPS6KA3-Tyr234
Cancer	Intensity
BRCA	0.971
COAD	0.41
HGSC	-0.822
ccRCC	0.314
GBM
HNSC	0.834
LUAD	0.151
LUSC	-0.301
non_ccRCC	-2.209
PDAC	0.653
UCEC

RPS6KA3-Tyr580
Cancer	Intensity
BRCA
COAD	-0.524
HGSC	1.411
ccRCC	-0.489
GBM	0.03
HNSC	0.273
LUAD	0.909
LUSC
non_ccRCC
PDAC
UCEC	-1.61

RPS6KA4-Ser196
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA4-Ser324
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	0.707
LUSC
non_ccRCC	-0.707
PDAC
UCEC

RPS6KA4-Ser343
Cancer	Intensity
BRCA
COAD	-0.444
HGSC	-0.405
ccRCC	-0.939
GBM
HNSC
LUAD	1.655
LUSC
non_ccRCC
PDAC
UCEC	0.133

RPS6KA4-Ser347
Cancer	Intensity
BRCA	-1.576
COAD	-0.393
HGSC	-1.669
ccRCC	0.108
GBM	0.057
HNSC	0.923
LUAD	0.922
LUSC	1.571
non_ccRCC	-0.416
PDAC	0.466
UCEC	0.008

RPS6KA4-Ser360
Cancer	Intensity
BRCA
COAD	0.371
HGSC
ccRCC	0.761
GBM
HNSC
LUAD	-1.132
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA4-Ser427
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.084
GBM
HNSC	-0.889
LUAD	-0.799
LUSC	1.602
non_ccRCC
PDAC	0.002
UCEC

RPS6KA4-Ser628
Cancer	Intensity
BRCA	1.139
COAD
HGSC
ccRCC
GBM
HNSC	-0.541
LUAD	0.271
LUSC	0.457
non_ccRCC	0.397
PDAC	-1.723
UCEC

RPS6KA4-Ser666
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA4-Ser672
Cancer	Intensity
BRCA
COAD	-0.511
HGSC	1.497
ccRCC	-0.415
GBM
HNSC	-0.571
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA4-Ser675
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.151
GBM
HNSC	-1.067
LUAD	0.916
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA4-Ser676
Cancer	Intensity
BRCA
COAD	-0.555
HGSC	2.167
ccRCC	-0.537
GBM	0.178
HNSC	-0.397
LUAD	-0.149
LUSC
non_ccRCC
PDAC
UCEC	-0.707

RPS6KA4-Ser715
Cancer	Intensity
BRCA	2.005
COAD	0.871
HGSC
ccRCC	0.372
GBM	0.047
HNSC	-0.041
LUAD	-0.146
LUSC	-0.063
non_ccRCC	-0.639
PDAC	-0.59
UCEC	-1.816

RPS6KA4-Ser731
Cancer	Intensity
BRCA	0.181
COAD
HGSC	2.352
ccRCC	-0.05
GBM
HNSC	-0.665
LUAD	-0.521
LUSC
non_ccRCC	-0.303
PDAC	-0.24
UCEC	-0.754

RPS6KA4-Ser739
Cancer	Intensity
BRCA	-0.305
COAD	-0.318
HGSC	2.006
ccRCC	-0.002
GBM	-1.495
HNSC	-0.449
LUAD	-0.039
LUSC	0.281
non_ccRCC	1.522
PDAC	-0.26
UCEC	-0.939

RPS6KA4-Thr22
Cancer	Intensity
BRCA	0.583
COAD	0.096
HGSC	2.1
ccRCC	0.142
GBM
HNSC	-0.848
LUAD	-0.29
LUSC	-0.293
non_ccRCC
PDAC	0.036
UCEC	-1.526

RPS6KA4-Thr681
Cancer	Intensity
BRCA	0.185
COAD	-0.107
HGSC	2.543
ccRCC	-0.339
GBM	0.659
HNSC	-0.152
LUAD	-0.452
LUSC	-0.578
non_ccRCC	0.101
PDAC	-1.494
UCEC	-0.366

RPS6KA4-Thr733
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA4-Tyr532
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC	-0.707

RPS6KA5-Ser176
Cancer	Intensity
BRCA
COAD	-0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

RPS6KA5-Ser340
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KA5-Ser448
Cancer	Intensity
BRCA	1.483
COAD
HGSC
ccRCC	-0.363
GBM
HNSC
LUAD	-0.413
LUSC	-0.707
non_ccRCC
PDAC
UCEC

RPS6KA5-Thr216
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.791
GBM
HNSC
LUAD	-1.124
LUSC	0.333
non_ccRCC
PDAC
UCEC

RPS6KA5-Thr38
Cancer	Intensity
BRCA	0.5
COAD
HGSC
ccRCC
GBM	0.303
HNSC
LUAD	1.047
LUSC	-0.272
non_ccRCC
PDAC
UCEC	-1.578

RPS6KB1-Ser371
Cancer	Intensity
BRCA
COAD	-0.707
HGSC
ccRCC	0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KB1-Ser375
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KB1-Ser418
Cancer	Intensity
BRCA	-0.189
COAD	0.616
HGSC	1.605
ccRCC	-2.354
GBM	-0.189
HNSC	0.25
LUAD	0.135
LUSC	0.115
non_ccRCC
PDAC	-0.404
UCEC	0.416

RPS6KB1-Ser424
Cancer	Intensity
BRCA	-0.557
COAD	1.149
HGSC	1.838
ccRCC	-1.833
GBM	0.084
HNSC	0.253
LUAD	-0.453
LUSC	-0.048
non_ccRCC
PDAC	-0.577
UCEC	0.145

RPS6KB1-Ser429
Cancer	Intensity
BRCA	-0.199
COAD
HGSC	1.767
ccRCC
GBM	-0.531
HNSC
LUAD
LUSC	-0.418
non_ccRCC
PDAC
UCEC	-0.618

RPS6KB1-Thr376
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KB1-Thr389
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KB1-Thr421
Cancer	Intensity
BRCA	-1.122
COAD	1.552
HGSC
ccRCC	-1.395
GBM	-0.379
HNSC	0.47
LUAD	-0.284
LUSC	0.124
non_ccRCC
PDAC	-0.319
UCEC	1.351

RPS6KB2-Ser370
Cancer	Intensity
BRCA
COAD	-0.707
HGSC
ccRCC
GBM
HNSC	0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KB2-Ser416
Cancer	Intensity
BRCA	-2.003
COAD
HGSC
ccRCC	0.431
GBM
HNSC	0.572
LUAD	-0.371
LUSC	0.898
non_ccRCC
PDAC	-0.221
UCEC	0.694

RPS6KB2-Ser417
Cancer	Intensity
BRCA	-2.069
COAD	-0.427
HGSC
ccRCC	0.592
GBM
HNSC	0.653
LUAD	-0.343
LUSC	0.998
non_ccRCC
PDAC	-0.185
UCEC	0.782

RPS6KB2-Ser423
Cancer	Intensity
BRCA	-1.811
COAD	1.399
HGSC
ccRCC	-0.01
GBM
HNSC	0.155
LUAD	0.098
LUSC	1.125
non_ccRCC
PDAC	-0.534
UCEC	-0.421

RPS6KC1-Ser189
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.707
GBM
HNSC
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC

RPS6KC1-Ser190
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.727
GBM
HNSC	1.14
LUAD	-0.414
LUSC
non_ccRCC
PDAC
UCEC

RPS6KC1-Ser197
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.509
GBM	-0.406
HNSC	0.951
LUAD	1.622
LUSC	0.186
non_ccRCC	-1.313
PDAC
UCEC	-0.53

RPS6KC1-Ser269
Cancer	Intensity
BRCA
COAD	-0.144
HGSC	0.582
ccRCC
GBM	0.909
HNSC	-1.347
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KC1-Ser270
Cancer	Intensity
BRCA	1.354
COAD	-0.017
HGSC	-1.24
ccRCC
GBM
HNSC	0.509
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.608

RPS6KC1-Ser411
Cancer	Intensity
BRCA	2.387
COAD	0.436
HGSC	0.167
ccRCC	-0.77
GBM	-1.192
HNSC	-0.814
LUAD	-0.221
LUSC	-0.385
non_ccRCC	0.888
PDAC	0.138
UCEC	-0.634

RPS6KC1-Ser415
Cancer	Intensity
BRCA	0.663
COAD	0.316
HGSC	-2.558
ccRCC	0.214
GBM	-0.255
HNSC	-0.484
LUAD	0.596
LUSC	1.244
non_ccRCC	0.509
PDAC	0.314
UCEC	-0.56

RPS6KC1-Ser436
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.116
GBM	-1.661
HNSC	0.534
LUAD	0.041
LUSC
non_ccRCC
PDAC
UCEC	0.97

RPS6KC1-Ser437
Cancer	Intensity
BRCA	1.598
COAD	0.098
HGSC	-1.55
ccRCC
GBM	-0.185
HNSC
LUAD
LUSC
non_ccRCC	-0.01
PDAC
UCEC	0.048

RPS6KC1-Ser449
Cancer	Intensity
BRCA
COAD
HGSC	-0.636
ccRCC	0.306
GBM	-1.295
HNSC
LUAD	-0.856
LUSC	1.652
non_ccRCC	0.316
PDAC
UCEC	0.513

RPS6KC1-Ser516
Cancer	Intensity
BRCA	1.127
COAD	-2.454
HGSC	0.155
ccRCC	-0.193
GBM	-0.351
HNSC	0.288
LUAD	0.06
LUSC	0.76
non_ccRCC	0.053
PDAC	1.201
UCEC	-0.646

RPS6KC1-Ser546
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.38
GBM	1.215
HNSC	-0.565
LUAD	-1.03
LUSC
non_ccRCC
PDAC
UCEC

RPS6KC1-Ser548
Cancer	Intensity
BRCA
COAD
HGSC	0.746
ccRCC
GBM	0.39
HNSC
LUAD
LUSC
non_ccRCC
PDAC	-1.136
UCEC

RPS6KC1-Ser570
Cancer	Intensity
BRCA
COAD	-1.454
HGSC	0.138
ccRCC
GBM	0.639
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.677

RPS6KC1-Ser571
Cancer	Intensity
BRCA
COAD	-0.88
HGSC	1.435
ccRCC
GBM	-0.357
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.198

RPS6KC1-Ser584
Cancer	Intensity
BRCA	0.121
COAD	-0.189
HGSC	2.94
ccRCC	-0.34
GBM	-0.228
HNSC	-0.123
LUAD	-0.757
LUSC	-0.42
non_ccRCC	-0.449
PDAC	-0.372
UCEC	-0.184

RPS6KC1-Ser593
Cancer	Intensity
BRCA	-0.729
COAD	0.654
HGSC
ccRCC	-0.146
GBM	-0.406
HNSC	-0.14
LUAD	0.416
LUSC	1.15
non_ccRCC	0.897
PDAC	0.583
UCEC	-2.28

RPS6KC1-Ser596
Cancer	Intensity
BRCA	-0.352
COAD	0.789
HGSC
ccRCC	-0.09
GBM	-0.845
HNSC	-0.714
LUAD	0.184
LUSC	0.578
non_ccRCC	1.859
PDAC	0.345
UCEC	-1.755

RPS6KC1-Ser598
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC	-0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

RPS6KC1-Ser628
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

RPS6KC1-Ser632
Cancer	Intensity
BRCA	-1.983
COAD	0.095
HGSC	-0.579
ccRCC	0.025
GBM	0.599
HNSC	-0.658
LUAD	0.178
LUSC	0.157
non_ccRCC	2.186
PDAC	0.212
UCEC	-0.232

RPS6KC1-Ser649
Cancer	Intensity
BRCA	1.779
COAD	0.743
HGSC
ccRCC	-0.775
GBM	-0.53
HNSC
LUAD	-0.558
LUSC	0.331
non_ccRCC
PDAC
UCEC	-0.99

RPS6KC1-Ser652
Cancer	Intensity
BRCA
COAD	0.369
HGSC	-2.416
ccRCC	0.254
GBM	0.043
HNSC	0.52
LUAD	0.137
LUSC
non_ccRCC
PDAC	0.74
UCEC	0.352

RPS6KC1-Ser655
Cancer	Intensity
BRCA	0.283
COAD	-0.475
HGSC	2.861
ccRCC	-0.544
GBM	-0.389
HNSC	0.282
LUAD	-0.378
LUSC	-0.631
non_ccRCC	-0.563
PDAC	-0.115
UCEC	-0.329

RPS6KC1-Ser750
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	0.554
HNSC	0.803
LUAD	-0.186
LUSC	-1.665
non_ccRCC	0.493
PDAC
UCEC

RPS6KC1-Ser860
Cancer	Intensity
BRCA	-1.779
COAD
HGSC
ccRCC	0.895
GBM	0.318
HNSC	-1.037
LUAD	-0.903
LUSC	0.988
non_ccRCC	0.45
PDAC	0.918
UCEC	0.15

RPS6KC1-Thr647
Cancer	Intensity
BRCA	1.814
COAD
HGSC
ccRCC	-0.458
GBM	-0.758
HNSC
LUAD	-0.475
LUSC	0.526
non_ccRCC
PDAC
UCEC	-0.65

RPS6KC1-Thr847
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.772
GBM
HNSC
LUAD	1.13
LUSC	-0.357
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
S	244	U	Tuberous sclerosis complex	Phosphorylation	17671177
S	244	U	Liver cancer	Phosphorylation	23537100

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

Protein	Gene	PTM	Position	Modified sequence	Cell	Drug	pEC50	Regulation
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	A431	Afatinib	7.6182	up
P62753	RPS6	P	Ser240;Ser244;Ser247	LSSLRAS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	2	up
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	A549	PD325901	5.5493	up
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	Ramos	Rituximab	-3.8003	up
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	Ramos	Rituximab	-4.6934	up
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	Ramos	Rituximab	-7.4771	up
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	Ramos	Rituximab	-7.4771	up
P62753	RPS6	P	Ser242;Ser244;Ser246	ASTS(ph)KS(ph)ES(ph)SQK	Ramos	Rituximab	-2.1732	up
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	Ramos	Rituximab	-2.2042	up
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	Ramos	Rituximab	-2.2138	up
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Afatinib	6.5308	down
P62753	RPS6	P	Ser235;Ser236;Thr241;Ser244;Ser247	RLS(ph)S(ph)LRAST(ph)SKS(ph)ESS(ph)QK	A431	Afatinib	6.327	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Afatinib	6.325	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Dasatinib	5.7329	down
P62753	RPS6	P	Ser235;Ser236;Ser244	RLS(ph)S(ph)LRASTSKS(ph)ESSQK	A549	AZD8055	8.4856	down
P62753	RPS6	P	Ser235;Ser236;Ser244	LS(ph)S(ph)LRASTSKS(ph)ESSQK	A549	AZD8055	7.971	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Dactolisib	8.5491	down
P62753	RPS6	P	Ser235;Ser236;Ser244	RLS(ph)S(ph)LRASTSKS(ph)ESSQK	A549	Dactolisib	8.4216	down
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Dactolisib	7.9619	down
P62753	RPS6	P	Ser236;Ser242;Ser244	LSS(ph)LRASTS(ph)KS(ph)ESSQK	A549	Dactolisib	7.911	down
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A549	Dactolisib	7.834	down
P62753	RPS6	P	Ser235;Ser236;Ser244	RLS(ph)S(ph)LRASTSKS(ph)ESSQK	A549	Dasatinib	6.5971	down
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Pictilisib	6.5208	down
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Pictilisib	6.5009	down
P62753	RPS6	P	Ser235;Ser240;Ser244	LS(ph)SLRAS(ph)TSKS(ph)ESSQK	A549	Pictilisib	6.3499	down
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A549	Pictilisib	6.1519	down
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	BT-474	Lapatinib	6.6831	down
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	MDA-MB-175	Lapatinib	6.8431	down
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	MDA-MB-175	Pertuzumab	-4.5865	down
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	RPMI8226	BTZ	8.7047	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	RPMI8226	BTZ	8.6859	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	8.6825	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	RPMI8226	BTZ	8.6181	down
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	RPMI8226	BTZ	8.5146	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	RPMI8226	BTZ	8.4941	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	8.4774	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	RPMI8226	BTZ	8.4568	down
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	RPMI8226	BTZ	8.0695	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	RPMI8226	BTZ	6.979	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	RPMI8226	BTZ	6.58	down
P62753	RPS6	P	Ser242;Ser244;Ser246	ASTS(ph)KS(ph)ES(ph)SQK	RPMI8226	BTZ	7.653	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	RPMI8226	BTZ	8.7098	down
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	RPMI8226	BTZ	8.3173	down
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	8.3073	down
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	7.8181	down
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	RPMI8226	BTZ	7.6649	down
P62753	RPS6	P	Ser242;Ser244;Ser246	ASTS(ph)KS(ph)ES(ph)SQK	RPMI8226	BTZ	9.1584	down
P62753	RPS6	P	Ser242;Ser244;Ser246	ASTS(ph)KS(ph)ES(ph)SQK	RPMI8226	BTZ	8.4091	down
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	RPMI8226	BTZ	8.3784	down
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Afatinib	14.17	-
P62753	RPS6	P	Ser240;Ser244	AS(ph)TSKS(ph)ESSQK	A431	Afatinib	8.7599	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	A431	Afatinib	8.7431	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A431	Afatinib	8.5365	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	A431	Afatinib	7.8745	-
P62753	RPS6	P	Ser235;Ser236;Ser244;Ser246	RLS(ph)S(ph)LRASTSKS(ph)ES(ph)SQK	A431	Afatinib	7.5255	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Afatinib	6.8489	-
P62753	RPS6	P	Ser240;Ser244	LSSLRAS(ph)TSKS(ph)ESSQK	A431	Afatinib	6.8128	-
P62753	RPS6	P	Ser236;Thr241;Ser244;Ser246	RLSS(ph)LRAST(ph)SKS(ph)ES(ph)SQK	A431	Afatinib	2	-
P62753	RPS6	P	Thr241;Ser244;Ser246	AST(ph)SKS(ph)ES(ph)SQK	A431	Afatinib	8.1918	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	A431	Afatinib	8.1313	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	A431	Afatinib	7.9872	-
P62753	RPS6	P	Ser240;Ser244	AS(ph)TSKS(ph)ESSQK	A431	Afatinib	2	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Afatinib	8.2793	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Afatinib	8.271	-
P62753	RPS6	P	Ser236;Ser240;Thr241;Ser244;Ser247	LSS(ph)LRAS(ph)T(ph)SKS(ph)ESS(ph)QK	A431	Afatinib	7.783	-
P62753	RPS6	P	Ser240;Ser244;Ser247	LSSLRAS(ph)TSKS(ph)ESS(ph)QK	A431	Afatinib	7.1496	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Afatinib	16.5229	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	A431	Afatinib	12.7667	-
P62753	RPS6	P	Ser235;Ser236;Ser242;Ser244	RLS(ph)S(ph)LRASTS(ph)KS(ph)ESSQK	A431	Afatinib	10.0658	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Afatinib	8.3866	-
P62753	RPS6	P	Ser244;Ser246	S(ph)ES(ph)SQK	A431	Afatinib	8.1529	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	A431	Afatinib	8.0677	-
P62753	RPS6	P	Ser240;Ser244;Ser247	LSSLRAS(ph)TSKS(ph)ESS(ph)QK	A431	Afatinib	7.7725	-
P62753	RPS6	P	Ser240;Ser244	LSSLRAS(ph)TSKS(ph)ESSQK	A431	Afatinib	7.6445	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser246	RLS(ph)SLRAS(ph)TSKS(ph)ES(ph)SQK	A431	Afatinib	7.2639	-
P62753	RPS6	P	Ser236;Ser240;Thr241;Ser244;Ser246	RLSS(ph)LRAS(ph)T(ph)SKS(ph)ES(ph)SQK	A431	Afatinib	2.1958	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Dasatinib	9.0468	-
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	A431	Dasatinib	7.9275	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A431	Dasatinib	7.3938	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Dasatinib	6.7511	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Dasatinib	6.5411	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A431	Dasatinib	6.2787	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Dasatinib	5.5937	-
P62753	RPS6	P	Ser235;Ser236;Ser244;Ser246	RLS(ph)S(ph)LRASTSKS(ph)ES(ph)SQK	A431	Dasatinib	5.4555	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Dasatinib	4.8888	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Dasatinib	4.8441	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Dasatinib	4.7228	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Dasatinib	6.7833	-
P62753	RPS6	P	Ser235;Ser236;Ser244;Ser246	RLS(ph)S(ph)LRASTSKS(ph)ES(ph)SQK	A431	Dasatinib	6.7571	-
P62753	RPS6	P	Ser240;Ser244;Ser247	LSSLRAS(ph)TSKS(ph)ESS(ph)QK	A431	Dasatinib	6.5341	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Dasatinib	5.5735	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	A431	Dasatinib	10.4592	-
P62753	RPS6	P	Ser236;Ser240;Thr241;Ser244;Ser246	LSS(ph)LRAS(ph)T(ph)SKS(ph)ES(ph)SQK	A431	Dasatinib	9.1126	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Dasatinib	8.9452	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	RLSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Dasatinib	8.93	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Dasatinib	8.8115	-
P62753	RPS6	P	Ser240;Ser244;Ser246	LSSLRAS(ph)TSKS(ph)ES(ph)SQK	A431	Dasatinib	8.7547	-
P62753	RPS6	P	Ser240;Ser244	LSSLRAS(ph)TSKS(ph)ESSQK	A431	Dasatinib	8.7516	-
P62753	RPS6	P	Ser236;Ser240;Ser242;Ser244;Ser247	LSS(ph)LRAS(ph)TS(ph)KS(ph)ESS(ph)QK	A431	Dasatinib	7.762	-
P62753	RPS6	P	Ser244	S(ph)ESSQK	A431	Dasatinib	7.2724	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	A431	Dasatinib	13.6805	-
P62753	RPS6	P	Ser236;Ser240;Thr241;Ser244;Ser246	RLSS(ph)LRAS(ph)T(ph)SKS(ph)ES(ph)SQK	A431	Dasatinib	11.0371	-
P62753	RPS6	P	Ser240;Ser244	LSSLRAS(ph)TSKS(ph)ESSQK	A431	Dasatinib	8.4897	-
P62753	RPS6	P	Ser236;Ser240;Thr241;Ser244;Ser247	LSS(ph)LRAS(ph)T(ph)SKS(ph)ESS(ph)QK	A431	Dasatinib	5.3773	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Dasatinib	2	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Gefitinib	8.1934	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	7.7144	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	7.0074	-
P62753	RPS6	P	Ser240;Ser244;Ser246	LSSLRAS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	6.9665	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	A431	Gefitinib	6.6688	-
P62753	RPS6	P	Thr241;Ser244;Ser247	AST(ph)SKS(ph)ESS(ph)QK	A431	Gefitinib	6.6204	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	4.8806	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	A431	Gefitinib	12.4375	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	10.4928	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser246	RLS(ph)SLRAS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	8.2569	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	RLSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	8.2519	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	8.0232	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Gefitinib	7.2872	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	6.4162	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Gefitinib	6.3613	-
P62753	RPS6	P	Ser236;Ser240;Ser242;Ser244;Ser247	LSS(ph)LRAS(ph)TS(ph)KS(ph)ESS(ph)QK	A431	Gefitinib	9.8244	-
P62753	RPS6	P	Ser244;Ser246	S(ph)ES(ph)SQK	A431	Gefitinib	9.2748	-
P62753	RPS6	P	Ser240;Ser244;Ser246	LSSLRAS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	9.2656	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	9.2594	-
P62753	RPS6	P	Ser240;Ser244	LSSLRAS(ph)TSKS(ph)ESSQK	A431	Gefitinib	9.2539	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	6.7892	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Gefitinib	5.3659	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	16.0229	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser246	RLS(ph)SLRAS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	8.5104	-
P62753	RPS6	P	Ser240;Ser244;Ser247	LSSLRAS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	7.0391	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Gefitinib	6.325	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Gefitinib	6.2223	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	A431	Gefitinib	6.1668	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A431	Gefitinib	6.1406	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A431	Imatinib	10.5737	-
P62753	RPS6	P	Ser235;Ser236;Thr241;Ser244;Ser247	RLS(ph)S(ph)LRAST(ph)SKS(ph)ESS(ph)QK	A431	Imatinib	10.3435	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser246	RLS(ph)SLRAS(ph)TSKS(ph)ES(ph)SQK	A431	Imatinib	9.0853	-
P62753	RPS6	P	Ser240;Ser244;Ser246	LSSLRAS(ph)TSKS(ph)ES(ph)SQK	A431	Imatinib	7.6636	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Imatinib	7.0851	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	A431	Imatinib	6.9285	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	A431	Imatinib	5.4144	-
P62753	RPS6	P	Ser240;Ser244;Ser246	RLSSLRAS(ph)TSKS(ph)ES(ph)SQK	A549	AZD8055	8.0507	-
P62753	RPS6	P	Ser240;Ser244;Ser247	LSSLRAS(ph)TSKS(ph)ESS(ph)QK	A549	AZD8055	7.2506	-
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	A549	AZD8055	6.7627	-
P62753	RPS6	P	Thr241;Ser244;Ser247	RLSSLRAST(ph)SKS(ph)ESS(ph)QK	A549	Dactolisib	7.7601	-
P62753	RPS6	P	Ser242;Ser244;Ser247	LSSLRASTS(ph)KS(ph)ESS(ph)QK	A549	Dactolisib	7.5446	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	A549	Dactolisib	7.5357	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A549	Dasatinib	7.2361	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Dasatinib	4.7038	-
P62753	RPS6	P	Ser235;Ser240;Ser244	RLS(ph)SLRAS(ph)TSKS(ph)ESSQK	A549	Dasatinib	4.0161	-
P62753	RPS6	P	Ser240;Ser244;Ser247	RLSSLRAS(ph)TSKS(ph)ESS(ph)QK	A549	Dasatinib	2	-
P62753	RPS6	P	Ser235;Ser236;Ser244	LS(ph)S(ph)LRASTSKS(ph)ESSQK	A549	Dasatinib	2	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A549	Dasatinib	2	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Nintedanib	15	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A549	Nintedanib	8.7826	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	A549	Nintedanib	7.8317	-
P62753	RPS6	P	Ser235;Ser236;Ser244;Ser246	RLS(ph)S(ph)LRASTSKS(ph)ES(ph)SQK	A549	Nintedanib	5.6771	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Nintedanib	4.9093	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	PD325901	15	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser246;Ser247	RLS(ph)SLRAS(ph)TSKS(ph)ES(ph)S(ph)QK	A549	PD325901	10.9207	-
P62753	RPS6	P	Ser235;Ser240;Thr241;Ser244;Ser247	RLS(ph)SLRAS(ph)T(ph)SKS(ph)ESS(ph)QK	A549	PD325901	10.7122	-
P62753	RPS6	P	Ser235;Ser240;Ser244	RLS(ph)SLRAS(ph)TSKS(ph)ESSQK	A549	PD325901	8.0413	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A549	PD325901	5.5952	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	PD325901	5.4874	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	A549	PD325901	4.7272	-
P62753	RPS6	P	Ser240;Ser244;Ser246	LSSLRAS(ph)TSKS(ph)ES(ph)SQK	A549	Pictilisib	7.7642	-
P62753	RPS6	P	Ser236;Thr241;Ser244	RLSS(ph)LRAST(ph)SKS(ph)ESSQK	A549	Refametinib	9.4214	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Refametinib	6.602	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser246;Ser247	RLS(ph)SLRAS(ph)TSKS(ph)ES(ph)S(ph)QK	A549	Refametinib	6.3401	-
P62753	RPS6	P	Ser235;Ser236;Ser244	LS(ph)S(ph)LRASTSKS(ph)ESSQK	A549	Refametinib	5.7766	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	A549	Tideglusib	11.4792	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	A549	Tideglusib	11.091	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	A549	Tideglusib	8.7798	-
P62753	RPS6	P	Ser236;Ser244	RLSS(ph)LRASTSKS(ph)ESSQK	A549	Tideglusib	7.7481	-
P62753	RPS6	P	Ser240;Ser244;Ser246	RLSSLRAS(ph)TSKS(ph)ES(ph)SQK	A549	Tideglusib	5.7636	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser246	RLS(ph)SLRAS(ph)TSKS(ph)ES(ph)SQK	A549	Tideglusib	5.749	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser246;Ser247	RLS(ph)SLRAS(ph)TSKS(ph)ES(ph)S(ph)QK	A549	Tideglusib	5.253	-
P62753	RPS6	P	Ser236;Thr241;Ser244;Ser246	LSS(ph)LRAST(ph)SKS(ph)ES(ph)SQK	A549	Tideglusib	4.272	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	ARH-77	Rituximab	-1.2469	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	ARH-77	Rituximab	-3.9855	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	ARH-77	Rituximab	-4.2383	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	ARH-77	Rituximab	-4.2478	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	ARH-77	Rituximab	-4.2931	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	BT-474	Lapatinib	6.7344	-
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	BT-474	Pertuzumab	-1.9824	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	BT-474	Trastuzumab	-1.7024	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	BT-474	Trastuzumab	-2.7346	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Dasatinib	14.868	-
P62753	RPS6	P	Ser236;Ser240;Ser242;Ser244;Ser247	LSS(ph)LRAS(ph)TS(ph)KS(ph)ESS(ph)QK	K562	Dasatinib	9.2751	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Dasatinib	8.6575	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Dasatinib	8.5261	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	K562	Dasatinib	8.0172	-
P62753	RPS6	P	Ser235;Ser236;Thr241;Ser244;Ser246	RLS(ph)S(ph)LRAST(ph)SKS(ph)ES(ph)SQK	K562	Dasatinib	6.8092	-
P62753	RPS6	P	Ser235;Ser236;Thr241;Ser244;Ser247	RLS(ph)S(ph)LRAST(ph)SKS(ph)ESS(ph)QK	K562	Dasatinib	6.5772	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	K562	Dasatinib	6.1358	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Dasatinib	5.6801	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	K562	Dasatinib	5.5901	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	K562	Dasatinib	3.8811	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser247	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	K562	Dasatinib	9.278	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Dasatinib	9.2519	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	K562	Dasatinib	9.7346	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Dasatinib	8.9762	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	K562	Imatinib	9.6305	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Imatinib	9.4662	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	K562	Imatinib	8.2736	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Imatinib	7.0556	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	K562	Imatinib	6.7357	-
P62753	RPS6	P	Ser235;Ser236;Thr241;Ser244;Ser247	RLS(ph)S(ph)LRAST(ph)SKS(ph)ESS(ph)QK	K562	Imatinib	6.6426	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	K562	Imatinib	6.6078	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	RLSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	K562	Imatinib	5.7761	-
P62753	RPS6	P	Ser236;Ser240;Ser242;Ser244;Ser247	LSS(ph)LRAS(ph)TS(ph)KS(ph)ESS(ph)QK	K562	Imatinib	5.29	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	MDA-MB-175	Trastuzumab	-3.2367	-
P62753	RPS6	P	Ser235;Ser236;Ser244	RLS(ph)S(ph)LRASTSKS(ph)ESSQK	MDA-MB-175	Trastuzumab	-3.2511	-
P62753	RPS6	P	Ser235;Ser240;Ser244;Ser247	LS(ph)SLRAS(ph)TSKS(ph)ESS(ph)QK	Ramos	Rituximab	-0.192	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	Ramos	Rituximab	-0.4434	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	Ramos	Rituximab	-3.2425	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	Ramos	Rituximab	-3.2467	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	Ramos	Rituximab	-3.2494	-
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	Ramos	Rituximab	-3.2705	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	Ramos	Rituximab	-6.2911	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	Ramos	Rituximab	-2.7284	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	Ramos	Rituximab	-2.7325	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	Ramos	Rituximab	-2.8359	-
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	Ramos	Rituximab	-2.8959	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	Ramos	Rituximab	-3.7993	-
P62753	RPS6	P	Ser236;Ser240;Ser244	LSS(ph)LRAS(ph)TSKS(ph)ESSQK	Ramos	Rituximab	-1.5227	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	Ramos	Rituximab	-1.5352	-
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	Ramos	Rituximab	-1.6068	-
P62753	RPS6	P	Ser236;Ser240;Ser244	RLSS(ph)LRAS(ph)TSKS(ph)ESSQK	Ramos	Rituximab	-1.6432	-
P62753	RPS6	P	Ser236;Thr241;Ser244	LSS(ph)LRAST(ph)SKS(ph)ESSQK	Ramos	Rituximab	-1.8054	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	Ramos	Rituximab	-2.6991	-
P62753	RPS6	P	Ser240;Ser244;Ser247	AS(ph)TSKS(ph)ESS(ph)QK	Ramos	Rituximab	-2.7135	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	Ramos	Rituximab	-3.0835	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	Ramos	Rituximab	-3.4202	-
P62753	RPS6	P	Ser240;Ser244;Ser246	LSSLRAS(ph)TSKS(ph)ES(ph)SQK	Ramos	Rituximab	-1.0799	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser247	LSS(ph)LRAS(ph)TSKS(ph)ESS(ph)QK	Ramos	Rituximab	-1.1815	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	Ramos	Rituximab	-7.4771	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	8.529	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	RPMI8226	BTZ	7.8853	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	RPMI8226	BTZ	6.6296	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	6.5035	-
P62753	RPS6	P	Ser244;Ser246	ASTSKS(ph)ES(ph)SQK	RPMI8226	BTZ	6.4127	-
P62753	RPS6	P	Ser240;Ser244;Ser246	AS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	6.2771	-
P62753	RPS6	P	Ser236;Ser240;Ser244;Ser246	LSS(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	5.5193	-
P62753	RPS6	P	Ser242;Ser244;Ser246	ASTS(ph)KS(ph)ES(ph)SQK	RPMI8226	BTZ	7.3888	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	7.3223	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244;Ser246	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ES(ph)SQK	RPMI8226	BTZ	6.8929	-
P62753	RPS6	P	Ser235;Ser236;Ser240;Ser244	RLS(ph)S(ph)LRAS(ph)TSKS(ph)ESSQK	RPMI8226	BTZ	8.7767	-
P62753	RPS6	P	Ser244;Ser247	ASTSKS(ph)ESS(ph)QK	RPMI8226	BTZ	8.4455	-
P62753	RPS6	P	Ser244	ASTSKS(ph)ESSQK	SK-BR-3	Trastuzumab	-1.54	-

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb